Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | GLP1R | P43220 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12186857 | 1.00 | LRRK2 (0.38) | LRRK2XDHGLP1RALDH1A1TP53 | |
| SCHEMBL9884946 | 1.00 | LRRK2 (0.38) | LRRK2XDHGLP1RALDH1A1TP53 | |
| SCHEMBL252006 | 0.87 | ADORA2A (0.42) | XDHADORA3ADORA2AADORA1 | |
| SCHEMBL9925919 | 0.86 | XDH (0.36) | XDHADORA3ADORA2AADORA1 | |
| SCHEMBL9884947 | 0.86 | XDH (0.36) | XDHADORA3ADORA2AADORA1 | |
| SCHEMBL9884944 | 0.86 | XDH (0.36) | XDHADORA3ADORA2AADORA1 | |
| SCHEMBL12186854 | 0.84 | XDH (0.41) | LRRK2XDHGLP1RTDP1GAA | |
| SCHEMBL252905 | 0.84 | NPSR1 (0.43) | LRRK2GLP1RALDH1A1TP53HSP90AA1 | |
| SCHEMBL9925941 | 0.84 | NPSR1 (0.43) | LRRK2GLP1RALDH1A1TP53HSP90AA1 | |
| SCHEMBL4572176 | 0.84 | NPSR1 (0.43) | LRRK2GLP1RALDH1A1TP53HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2017-10-05 | — | — | US | disclosed |
| US-9738644-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9655892-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2017-05-23 | — | — | US | disclosed |
| EP-3150609-A1 | PROCESS FOR PREPARING CERTAIN CHEMICAL ENTITIES | Intellikine, LLC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9527847-B2 | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9522146-B2 | Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE LLC (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160158239-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160113932-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160031886-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2016-02-04 | — | — | US | disclosed |
| WO-2014071105-A1 | TREATMENT OF RHEUMATOID ARTHRITIS AND ASTHMA USING P13 KINASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20140120083-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2014004470-A1 | TREATMENT OF LUPUS, FIBROTIC CONDITIONS, AND INFLAMMATORY MYOPATHIES AND OTHER DISORDERS USING PI3 KINASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| US-8569323-B2 | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2012-12-27 | — | — | US | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| WO-2011146882-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INTELLIKINE, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011008302-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | LRRK2 613/4885XDH 3120/4885GLP1R 3503/4885 |
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | LRRK2 613/4885XDH 3120/4885GLP1R 3503/4885 |
| US-20160113932-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, PIK3CG, PIK3CD | LRRK2 3869/4885XDH 4245/4885GLP1R 1253/4885 |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | LRRK2 918/4885XDH 2416/4885GLP1R 3668/4885 |
| US-20160158239-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | LRRK2 918/4885XDH 2416/4885GLP1R 3668/4885 |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | LRRK2 2108/4885XDH 3759/4885GLP1R 3719/4885 |
| US-20140120083-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | LRRK2 2108/4885XDH 3759/4885GLP1R 3719/4885 |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | LRRK2 706/4885XDH 1004/4885GLP1R 2253/4885 |
| US-20160031886-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | LRRK2 712/4885XDH 1361/4885GLP1R 2180/4885 |
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | LRRK2 712/4885XDH 1361/4885GLP1R 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.